Full-Time

National Training Manager

Confirmed live in the last 24 hours

Axsome Therapeutics Inc

Axsome Therapeutics Inc

201-500 employees

Develops therapies for CNS disorders

Compensation Overview

$140k - $160k/yr

+ Bonus + Equity

Mid, Senior

New York, NY, USA

Hybrid

This position requires up to 50% travel based on recurring national, regional, and HQ-based training events.

Category
Training
Requirements
  • Bachelor’s degree required
  • 3+ years of field sales experience in pharmaceutical industry
  • Prior regional based or field based training experience
  • Ability to travel up to 50%, including support for field rides, Nationals Sales Meetings, POAs and product launch meetings, based on business needs
Responsibilities
  • Conduct all foundational new hire and advanced sales training classes virtually with some in-person sessions
  • Coach and support new specialty account managers in their onboarding
  • Partnering with the HQ based training team and cross functional teams, manage all aspects of training logistics for assigned classes to ensure a seamless learning experience for newly hired sales professionals
  • Engage in and support in the design, development, and implementation of training national and regional training events
  • Support and at times oversee, the submission of training materials through the promotional review process to ensure materials are current, compliant and aligned with strategic learning priorities
  • Evaluate and address the training needs of the sales team by collaborating with commercial and sales leaders
  • Conduct field-rides with specialty account managers to provide continued learning support for our field teams
  • Conduct live training and National Sales Meetings and plan of Action meetings
  • Stay informed about industry regulations and guidelines related to pharmaceutical sales and marketing, ensuring all training content adheres to compliance standards and ethical practices
Desired Qualifications
  • Experience in presenting to live/virtual audiences of various sizes and tenure
  • Demonstrated success in facilitating training in both classroom and virtual settings
  • Proven expertise in collaborating with individuals across various management levels
  • Experience in the CNS therapeutic area is strongly preferred
Axsome Therapeutics Inc

Axsome Therapeutics Inc

View

Axsome Therapeutics develops therapies for central nervous system (CNS) disorders, focusing on conditions like major depressive disorder, treatment-resistant depression, Alzheimer's agitation, migraine, narcolepsy, fibromyalgia, and smoking cessation. Their main product, AXS-05, is an oral medication that acts as an NMDA receptor antagonist, blocking brain receptors involved in mood regulation. This drug has shown promise in clinical trials and has received FDA Breakthrough Therapy Designation, which speeds up its development process. Axsome stands out from competitors by concentrating on unmet medical needs in CNS disorders and advancing its drug pipeline through rigorous trials and regulatory approvals. The company's goal is to bring effective treatments to market to improve patient outcomes and quality of life.

Company Size

201-500

Company Stage

IPO

Headquarters

New York City, New York

Founded

2012

Simplify Jobs

Simplify's Take

What believers are saying

  • Axsome's expansion in NYC indicates growth and increased operational capacity.
  • The $570 million credit facility with Blackstone provides financial flexibility for growth.
  • Positive Phase 3 results for AXS-05 and AXS-12 boost market confidence.

What critics are saying

  • Increased competition in CNS disorder treatments could impact market share.
  • The $570 million loan may strain financial resources and cash flow.
  • Reliance on AXS-05's success poses a risk if clinical trials face setbacks.

What makes Axsome Therapeutics Inc unique

  • Axsome focuses on CNS disorders, addressing unmet medical needs in this area.
  • The company has a balanced portfolio of clinical and research stage products.
  • AXS-05, a flagship product, has FDA Breakthrough Therapy Designation.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Company Equity

Company News

Axsomet Therapeutics Inc.
Jul 7th, 2025
Axsome Therapeutics to Showcase Its Innovative CNS Pipeline at Upcoming Frontiers in Brain Health R&D Day in New York City on July 21

NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) - Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will host its Frontiers in Brain Health R&D Day on July 21, 2025, starting at 11:00 a.m. Eastern Time in New York City.

EMPR
Jun 10th, 2025
Symbravo Now Available for the Acute Treatment of Migraine

Axsome Therapeutics announces availability of Symbravo(R) (meloxicam and rizatriptan) for the acute treatment of migraine with or without aura in adults.

Intelligence360
Jun 3rd, 2025
Axsome Therapeutics Plans 96,000 Sq.Ft. Expansion In New York City.

Axsome Therapeutics plans 96,000 Sq.Ft. expansion in New York City. Axsome Therapeutics plans 96,000 Sq.Ft. expansion in New York City.New York, New York — According to state and local development sources, Axsome Therapeutics plans to build out 96,000 square feet of new space in New York. The company plans to occupy the new space in New York, on or about December 1, 2025. According to the company website Axsome Therapeutics, Inc

Stock Titan
May 13th, 2025
Axsome Therapeutics Enters $570 Million Term Loan and Revolving Credit Facility with Blackstone

Axsome Therapeutics (NASDAQ: AXSM) has secured a $570 million term loan and revolving credit facility with Blackstone, replacing its previous Hercules Capital term loan. The facility consists of a $500 million term loan and a $70 million revolving credit facility. The company initially drew $120 million to retire its previous loan.The new facility offers improved terms, including interest rates of SOFR plus 4.75% for the term loan and SOFR plus 4.0% for the revolving credit facility, with a 60-month interest-only period and maturity in May 2030. Additionally, Blackstone purchased $15 million of Axsome common stock at $107.14 per share. The company can access an additional $250 million at its option, with another $200 million available subject to Blackstone's approval.

Life Care News
May 1st, 2025
Axsome Therapeutics and Mental Health America (MHA) Join Voices to Highlight Mental Health Month

NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) - Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it is joining with Mental Health America (MHA) and the broader mental health advocacy community in a consolidated effort to raise awareness and promote action during May's Mental Health Month.